对于非酒精性型肝炎 - 建模方法和验证的De Novo成本效益模型框架
Peter Gal1, Gyorgyi Feldmajer1, Margarida Augusto2
1Evidera, Budapest, Hungary.
PharmacoEconomics
|July 28, 2023
概括
这项研究开发了一种新的非酒精性脂肪肝炎 (NASH) 的成本效益模型,其中包括并发症. 该模型旨在通过考虑肝外疾病状态,更好地估计NASH干预措施的成本效益.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
背景情况:
- 非酒精性脂肪肝炎 (NASH) 是一种慢性肝病,具有显著的肝脏和肝外发病率.
- 现有的NASH的成本效益模型 (CEM) 往往忽略了关键的并发症条件.
- 这种异质性限制了对NASH干预措施的准确评估.
研究的目的:
- 为NASH开发一个新的,新的成本效益模型 (CEM) 框架.
- 将肝外疾病状态和结果与肝部件一起纳入.
- 为了使NASH干预措施的成本效益能够在未来估计.
主要方法:
- 开发了一种混合患者级模拟和队列级马尔科夫模型框架.
- 模型输入包括纤维化进展,肝病结果,并发症结果 (心血管疾病,2型糖尿病,肥胖症),死亡率,生活质量和成本.
- 疗效和不良事件数据来源于REGENERATE试验的中间分析.
主要成果:
- 原型分析显示,与标准护理相比,obeticholic acid增加了总成本,寿命年和质量调整的寿命年.
- 与现有模型的交叉验证显示了显著的差异,主要是由于死亡率输入和并发症效应.
- 该模型强调了共患病对NASH成本效益的影响.
结论:
- 这是NASH CEM首次整合多种并发病的临床后果.
- 灵活的框架允许在不同的环境中进行成本效益估计.
- 随着更多数据的可用性,计划进一步开发.
相关概念视频
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
184
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
184
Pharmacokinetic Models: Comparison and Selection Criterion
109
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
109
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
95
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
95
Model Approaches for Pharmacokinetic Data: Physiological Models
78
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
78
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
61
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
61
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
96
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
96


